United Gene High-Tech Group Ltd revenue growth decelerated from 196% in FY2014 to 14.2% in FY2015
30/06/2015 • About United Gene High-Tech Group Ltd (
$399) • By InTwits
United Gene High-Tech Group Ltd reported FY2015 financial results today. Overall the company's long term financial model is characterised by the following facts:
- The company operates at negative EBITDA Margin: -122.1%
- United Gene High-Tech Group Ltd motivates its personel by high Stock Based Compensation (SBC): average SBC/Revenue for FY2011-FY2015 was 0.0%. On average EBITDA Margin was -62.5% for the sames years0
Below you can find a comprehensive analysis of the key data driving the company's performance and stock price.
United Gene High-Tech Group Ltd ($399) key annual financial indicators
| mln. | 2011 | 2012 | 2013 | 2014 | 2015 | 2015/2014 |
|---|
P&L
|
|---|
| Revenue | 90.193 | 25.475 | 10.050 | 29.744 | 33.976 | 14.2% |
| Gross Profit | 33.507 | 7.046 | -8.009 | | 0.918 | |
| SG&A | | 46.737 | 51.192 | | 27.890 | |
| EBITDA | 8.468 | -27.622 | -57.836 | | -41.477 | |
| Net Income | 5.247 | -123.882 | -72.839 | -550.347 | -451.684 | -17.9% |
Balance Sheet
|
|---|
| Cash | 222.267 | 169.815 | 355.253 | | 191.191 | |
| Short Term Debt | 0.000 | 4.907 | 6.910 | | 0.000 | |
| Long Term Debt | 0.000 | 6.133 | 14.963 | | 354.957 | |
Cash flow
|
|---|
| Capex | 23.262 | 27.913 | 5.283 | | 0.000 | |
Ratios
|
|---|
| Revenue growth | -81.4% | -71.8% | -60.5% | 196.0% | 14.2% | |
| EBITDA growth | -38.4% | -426.2% | 109.4% | | | |
| Gross Margin | 37.2% | 27.7% | -79.7% | | 2.7% | 2.7% |
| EBITDA Margin | 9.4% | -108.4% | -575.5% | 0.0% | -122.1% | -122.1% |
| Net Income Margin | 5.8% | -486.3% | -724.8% | -1,850.3% | -1,329.4% | 520.9% |
| SG&A, % of revenue | | 183.5% | 509.4% | | 82.1% | 82.1% |
| CAPEX, % of revenue | 25.8% | 109.6% | 52.6% | | 0.0% | 0.0% |
| ROIC | 1.5% | -8.6% | -17.2% | | | 0.0% |
| ROE | 1.2% | -32.8% | -18.9% | | | 0.0% |
| Net Debt/EBITDA | -26.2x | | | | | 0.0x |
Revenue and profitability
United Gene High-Tech Group Ltd's Revenue jumped on 14.2% in FY2015.
Net Income marign surged on 521 pp from -1,850% to -1,329% in FY2015.
Leverage (Debt)
Debt level is -5.0x Net Debt / EBITDA and Debt / EBITDA. Net Debt / EBITDA didn't change in FY2015. Debt surged while cash jumped.
Appendix 1: Peers in Pharmaceuticals
Below we provide United Gene High-Tech Group Ltd benchmarking against other companies in Pharmaceuticals industry for the last 5 years. We show data for the top-5 companies by key financial metric together with the median value for all the companies in the industry.
Top companies by Revenue growth, %
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|
| Hong Kong Life Sciences and Technology Group Ltd ($8085) | | -10.0% | -45.4% | 1,636.5% | -52.9% |
| Northeast Tiger Pharmaceutical Corp Ltd ($8197) | -17.7% | 15.1% | -99.9% | 480.0% | |
| China Traditional Chinese Medicine Co Ltd ($570) | 3.1% | 22.3% | 35.2% | 90.0% | |
| Dragonite International Ltd ($329) | -8.8% | -10.5% | 13.5% | 64.8% | |
| Tianda Pharmaceuticals Ltd ($455) | | -6.2% | 85.3% | 37.2% | -43.6% |
| |
|---|
| Median (38 companies) | 18.0% | 14.3% | 13.7% | 15.3% | -43.6% |
|---|
| United Gene High-Tech Group Ltd ($399) | | -71.8% | -60.5% | 196.0% | 14.2% |
Top companies by Gross margin, %
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|
| Jilin Province Huinan Changlong Bio-pharmacy Co Ltd ($8049) | 83.9% | 82.0% | 81.5% | 80.9% | |
| Consun Pharmaceutical Group Ltd ($1681) | 75.5% | 75.7% | 79.1% | 78.3% | |
| Sino Biopharmaceutical Ltd ($1177) | 78.5% | 78.5% | 77.5% | 76.4% | |
| China Health Group Inc ($8225) | 38.7% | 43.4% | 33.6% | 76.2% | |
| Hua Han Bio-Pharmaceutical Holdings Ltd ($587) | 72.6% | 65.2% | 77.9% | 72.1% | |
| |
|---|
| Median (37 companies) | 38.0% | 39.1% | 37.2% | 48.3% | 39.6% |
|---|
Top companies by EBITDA margin, %
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|
| Asia Resources Holdings Ltd ($899) | 3.5% | -80.8% | 25.1% | 113.7% | |
| Pak Fah Yeow International Ltd ($239) | 28.7% | 33.9% | 28.4% | 52.4% | |
| Real Nutriceutical Group Ltd ($2010) | 45.6% | 42.8% | 43.4% | 46.0% | |
| China Shineway Pharmaceutical Group Ltd ($2877) | 47.8% | 37.8% | 40.1% | 40.5% | |
| Lijun International Pharmaceutical Holding Co Ltd ($2005) | 6.2% | 21.5% | 35.9% | 38.9% | |
| |
|---|
| Median (38 companies) | 17.4% | 19.6% | 18.8% | 20.4% | -7.3% |
|---|
Top companies by CAPEX/Revenue, %
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|
| Northeast Tiger Pharmaceutical Corp Ltd ($8197) | 0.2% | | 11,100.0% | 103.4% | |
| Extrawell Pharmaceutical Holdings Ltd ($858) | 5.7% | 1.7% | 20.6% | 92.4% | 3.6% |
| Asia Resources Holdings Ltd ($899) | 12.2% | 4.4% | 8.1% | 92.0% | |
| Lijun International Pharmaceutical Holding Co Ltd ($2005) | 19.5% | 16.8% | 52.4% | 39.6% | |
| Hao Wen Holdings Ltd ($8019) | 6.4% | 30.0% | 2.3% | 38.2% | |
| |
|---|
| Median (38 companies) | 8.6% | 8.2% | 6.9% | 7.2% | 3.6% |
|---|
Top companies by ROIC, %
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|
| Jilin Province Huinan Changlong Bio-pharmacy Co Ltd ($8049) | 18.5% | 16.7% | 20.8% | 33.0% | |
| Sino Biopharmaceutical Ltd ($1177) | 19.9% | 26.2% | 26.8% | 26.5% | |
| Lee's Pharmaceutical Holdings Ltd ($950) | 31.3% | 26.1% | 22.0% | 22.4% | |
| Shandong Luoxin Pharmaceutical Group Stock Co Ltd ($8058) | 34.4% | 27.6% | 22.2% | 19.9% | |
| CSPC Pharmaceutical Group Ltd ($1093) | 9.9% | 14.5% | 12.8% | 18.1% | |
| |
|---|
| Median (38 companies) | 8.7% | 12.1% | 9.2% | 9.7% | -9.4% |
|---|
| United Gene High-Tech Group Ltd ($399) | 1.5% | -8.6% | -17.2% | | |
Top companies by Net Debt / EBITDA
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|
| China NT Pharma Group Co Ltd ($1011) | 0.4x | | | 7.2x | |
| United Laboratories International Holdings Ltd/The ($3933) | 4.4x | 6.5x | 4.6x | 4.2x | |
| Lansen Pharmaceutical Holdings Ltd ($503) | 0.9x | 1.7x | 2.8x | 3.4x | |
| China Grand Pharmaceutical and Healthcare Holdings Ltd ($512) | 2.5x | 5.4x | 4.0x | 3.4x | |
| Shandong Xinhua Pharmaceutical Co Ltd ($719) | 1.4x | 3.5x | 3.4x | 2.8x | |
| |
|---|
| Median (31 companies) | 0.1x | 0.0x | -0.1x | -0.5x | 9.9x |
|---|
